Latest Breaking News On - Skin structure infections - Page 4 : comparemela.com

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

Regulatory News: Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today. | April 28, 2023

United statesDarren luiAptorum group or weDaptorum groupAptorum group caymanSingapore agency for scienceHolding groupAptorum group formAptorum group limited nasdaqDrug administrationYu groupRegulatory newsGroup limitedEuronext parisChief executive officerExecutive director

Aptorum Group Limited: Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions

United statesDennis riedlClark chengCraig brelsfordGhislaine gasparettoAptorum group formAptorum group orDrug administrationSingapore agency for scienceActifin financial communications europeRedchip financial communications united statesDaptorum groupAptorum group limited nasdaqRegulatory newsGroup limitedEuronext paris

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Basel stadtUnited statesNils schrBasel allschwilAllschwil hegenheimermattwegMarc engelhardtAsahi kasei pharmaLaurenz kellenbergerDavid veitchUs department of healthHuman servicesBiomedical advanced researchDrug administrationMerck coAdministration for strategic preparednessDevelopment authority

Basilea Pharmaceutica AG: Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

Continued commercial success of Cresemba and Zevtera in 2022 generated revenue contributions of approx. CHF 122 million, exceeding guidance by more than 17%Significant proceeds from oncology transactionsFollowing

Basel stadtUnited statesNils schrBasel allschwilMarc engelhardtAsahi kasei pharmaLaurenz kellenbergerDavid veitchUs department of healthHuman servicesHead of corporate communications investor relationsBiomedical advanced researchDrug administrationMerck coAdministration for strategic preparednessDevelopment authority

Acute Bacterial Skin and Skin Structure Infections Global Market Report 2022: Acquisition of Drug Di

DUBLIN (BUSINESS WIRE) The "Acute Bacterial Skin and Skin Structure Infections Market, by Drug Type, by Infection Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.Acute.

United statesSouth africaSouth koreaAsia pacificLaura woodTennor therapeuticsAurobindo pharma ltdHydrogen peroxideMelinta therapeutics incParatek pharmaceuticals incSun pharmaceutical industries ltdTeva pharmaceutical industries ltdMerck co incPfizer incIntas pharmaceuticals ltdAbbvie inc